These responsibilities include some of the following: Establish pre-clinical oligonucleotide conjugation capabilities of ASOs, siRNA, SSO, and RNA editors with small molecules, lipids, linkers, and other conjugates with multistep synthesis from the milligram to gram scale. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients' needs and have the highest probability of success.